Deep learning for algorithmic detection of pulmonary hypertension using a combined digital stethoscope and single-lead electrocardiogram
Ended Project Grant Awarded Last action
- Award ID
- R44HL166025
- Recipient
-
EKO Health, Inc. UEI GM3UL6PBJKD3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,043,974
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Rhode Island, USA
Award details come from USAspending.gov.
Description
- Abstract
- This sbir direct to phase II project will develop a deep learning-based clinical decision support algorithm for screening and detecting pulmonary hypertension (PH) using phonocardiogram and electrocardiogram data recording using the EKO DUO digital stethoscopes. The screening tool will help to decrease the number of patients with pulmonary hypertension that remain undertreated simply because their condition is not diagnosed. The gold standard diagnostic for pulmonary hypertension is right heart catheterization which is costly, invasive, and requires specialized personnel.to address these challenges, EKO developed the DUO, a digital stethoscope in a handheld form factor with built-in single lead electrocardiogram. The DUO is designed to stream digitized phonocardiograms and electrocardiograms to a smartphone, tablet or personal computer. There, the signal can be analyzed with the decision support algorithm we developed as part of this project. The specific aims of this study are : (1) build a database of matched ECG/PCG recording labeled against right heart catheterization and echocardiograms, and (2) develop and clinically test a deep learning algorithm that can detect PH and stratify its severity. By integrating this deep learning algorithm into EKO's mobile and cloud software platform, we anticipate this algorithm will enable more accurate screening for pulmonary hypertension in adult patients, leading to earlier diagnosis and better patient outcomes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,108,862 | |
| Amendment | -$569,336 | |
| Amendment | -$175,264 | |
| Amendment | $1,105,764 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $786,974 | |
| Original award | $786,974 |
Show all 11
Quick answers
Who received award R44HL166025?
R44HL166025 was awarded to EKO Health, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 15, 2022.
How much is award R44HL166025 worth?
$3,043,974 has been obligated on R44HL166025.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award